[Funding alert] London-based Sable Bio Secures €1.7 Million in Pre-Seed Funding

Currently, the company is looking to collaborate with academic institutions and form alliances with biotech, pharma, and healthtech companies.

Read also - British Biotech FA Bio Raises €6.1 Million in Funding

With the help of the funds, they will be able to assemble an exceptional group of scientists and engineers, improve their core technology infrastructure, and lay a strong and wide base for their data capabilities.

Josh Almond-Thynne, Co-founder of Sable Bio, said: “We are really excited, this investment will help Sable Bio redefine drug safety assessment and change the ways actionable biomedical insights are generated. Working with leading investors Episode1 and Seedcamp is enabling us to build an exceptional team and a platform to accelerate safer drug development for patients in need”

Sable makes it easier for researchers in a variety of disciplines to obtain specialized biomedical data and use it to make well-informed decisions regarding the safety of particular therapeutic targets.

Read also - Dutch AI Startup Whispp Secures €750k in Seed Funding

Sable's method delivers significant time and cost savings in drug development, enabling the faster delivery of safer medications to patients in need. Unexpected toxicity is a key cause of failure in drug discovery campaigns.

Adam Shuaib, Partner at Episode 1, commented: “Target safety remains a critical hurdle in the drug discovery process, and as two rockstar scientists, Alex and Josh are uniquely positioned to solve such a complex problem. The advent of LLMs is a monumental technological shift that will help Sable Bio unlock swathes of data previously inaccessible within the scientific literature, ultimately reducing the time-to-market and costs associated with clinical trials”

Tom Wilson, Partner at SeedCamp, added: “Taking drugs to market from discovery to development and beyond takes far too long and toxicity is a major factor adding delays or causing such processes to fail entirely. Sable is perfectly positioned to solve this problem by providing access to the right data at the right time to those who need it, leveraging LLMs to surface data that would have previously been impossible to cover fully. Alex and Josh as co-founders have the ideal blend of scientific excellence, specific domain experience and entrepreneurially drive to be building Sable and we’re delighted to have the opportunity to partner with them“.

About Sable

Sable, a London-based company founded in 2023, uses a variety of cutting-edge methods to assist scientists in identifying and reducing potential safety hazards for medications that are either in research or about to go into clinical use.

Read also - Lyon-based ENYO Pharma Secures a €39 Million in Series C Round Funding